Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Stopped early · Phase 2
Conditions studied: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematologic and Lymphocytic Disorder, Hematopoietic Cell Transplantation Recipient, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis, T-Cell Non-Hodgkin Lymphoma, Thrombocytopenia, Venous Thromboembolism
In brief
This pilot clinical trial compares the safety of two different platelet transfusion "thresholds" among patients with blood cancer or treatment-induced thrombocytopenia whose condition requires anticoagulant medication (blood thinners) for blood clots. Giving relatively fewer platelet transfusions may reduce the side effects of frequent platelet transfusions without leading to undue bleeding.
Key facts
- Study ID
- NCT03195010
- Run by
- Fred Hutchinson Cancer Center
- People needed
- 4
- Starts
- 2017-06-09
- Expected to finish
- 2018-12-21
- Last updated by the study team
- 2019-10-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Any patient with non-acute promyelocytic leukemia (APL) acute leukemia (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], biphenotypic leukemia) undergoing curative intent chemotherapy OR any patient undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for a hematologic disorder (including acute leukemia as above, chronic myelogenous leukemia [CML], chronic lymphocytic leukemia [CLL], myelodysplastic syndrome [MDS], primary or secondary myelofibrosis, hypereosinophilic syndromes, plasma cell disorders, B-cell or T-cell lymphoma)
- Disease may be measurable or non-measurable
- Diagnosis of symptomatic venous thromboembolism requiring therapeutic-dose anticoagulation (unfractionated or low-molecular weight heparin or oral anticoagulants) throughout the period of hematopoietic recovery
- Anticipated platelet count =< 50 x 10\^9/L for >= 5 days within 72 hours of enrollment
- Ability to understand and the willingness to sign a written informed consent document
You may not qualify if…
- Separate episode of VTE or arterial thrombosis within 3 months of enrollment
- Major bleed (WHO grade 3 or 4) within 6 months of enrollment
- Active bleeding (grade 2 or higher) at the time of enrollment
- History of intracranial bleeding at any time
- Disorders of hemostasis including von Willebrand disease, hemophilia, platelet function disorders
- Concomitant use of aspirin or non-steroidal anti-inflammatory drugs
- Evidence of disseminated intravascular anticoagulation (DIC) as determined by the patient's primary provider
- History of alloimmunization (defined as platelet refractoriness with panel reactive antibody [PRA] > 25%) at the time of or prior to enrollment
- Uncontrolled or concurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris
- Psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or able to become pregnant and unwilling to use two forms of birth control during the study period
Where it is running
- Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.